Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Cardiff Oncology Inc (CRDF)

104 + Investors. Track Smart Money conviction in CRDF. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -8
Streak
1Q ▼
Buyers last Q
50%

Smart Money Signals — CRDF

Based on 106 hedge funds · latest filing: 2026 Q2 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their CRDF positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 90% of 3.0Y peak

90% of all-time peak
106 funds currently hold this stock — 90% of the 3.0-year high of 118 funds (reached 2025 Q1). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 9% fewer funds vs a year ago

fund count last 6Q
11 fewer hedge funds hold CRDF compared to a year ago (-9% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟡

Slight buying edge — 50% buying

59 buying60 selling
Last quarter: 59 funds bought or added vs 60 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
➡️

Steady new buyers — ~25 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 20 → 17 → 21 → 25. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

47% of holders stayed for 2+ years

■ 47% conviction (2yr+) ■ 28% medium ■ 25% new
50 out of 106 hedge funds have held CRDF for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares -25%, value -42%

Value
-41%
Shares
-25%
Last quarter: funds added -25% more shares while total portfolio value only changed -42%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📈

Growing discovery — still being found

19 → 20 → 17 → 21 → 25 new funds/Q
New funds entering each quarter: 20 → 17 → 21 → 25. A growing number of institutions are discovering CRDF each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.
🏛️

Veteran-anchored — 56% veterans vs 29% newcomers

■ 56% veterans ■ 15% 1-2yr ■ 29% new
Entry-cohort mix of 109 holders: 61 (56%) are 2+ year veterans, 16 entered 1–2 years ago, and 32 (29%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 31% AUM from major funds

31% from top-100 AUM funds
28 of 105 holders rank in the top 100 by AUM, accounting for 31% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.1
out of 10
Low Exit Risk
Exit risk score 3.1/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — CRDF

In 2026 Q2, 59 hedge funds were net buyers of CRDF (25 opened a new position, 34 added to an existing one), while 60 reduced or exited (27 trimmed, 33 sold completely) — a 50% buyer ratio, indicating a slight buying edge. 31% of total institutional value in CRDF is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -8 funds (more exits than new entries). Total institutional holders: 106.

Hedge Fund Ownership: CRDF

How many hedge funds hold CRDF — quarterly history vs. share price
Quarterly hedge fund ownership of CRDF vs. share price

Market Analysis: CRDF

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: CRDF

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Cardiff Oncology Inc (CRDF) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much CRDF has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 89d ago
CRDF
-4.6%
XLV
+8.0%

CRDF outperformed XLV by -12.6% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 44d ago
CRDF
+29.2%
XLV
+2.4%

Since the filing became public, CRDF outperformed XLV by +26.8% .

Interpretation: The stock has significantly outperformed its sector benchmark — the original entry opportunity has largely been captured by earlier investors. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

10 top-rated funds 0 high-conviction
Consensus
4.5
/ 10
breadth
×
Elite
0.5
/ 10
conviction
Hedge Fund Positioning: CRDF
104 + Investors

Track Smart Money conviction in CRDF. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 104 114 -8.77%
13F Shares 19M 25M -25.28%
Total Value $24M $41M -41.72%
New Positions 24 21 +3
Increased Positions 32 28 +4
Closed Positions 33 16 +17
Reduced Positions 27 38 -11
Total Calls 2 2 -
Total Puts 2 1 100.0%
PUT/CALL Ratio 1.0 0.5 Neutral

Statistics: CRDF

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

104 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CRDF. Verified SEC 13F-HR filings.

QUARTER:
Top 25 CRDF holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Pfizer Inc 1.77% 2,411,575 $3.0M
2 Laurion Capital Management LP 0.10% 3,098,299 $4.0M
3 Elkhorn Partners Limited Partnership 0.05% 48,000 $62K
4 Post Resch Tallon Group Inc. 0.02% 22,515 $29K
5 R Squared Ltd 0.02% 22,018 $29K
6 Avestar Capital, LLC 0.01% 136,145 $177K
7 Ledgewood Wealth Advisors, LLC 0.01% 11,190 $15K
8 Curated Wealth Partners LLC 0.01% 35,000 $41K
9 Proactive Wealth Strategies LLC 0.00% 20,000 $26K
10 Flputnam Investment Management Co 0.00% 247,474 $322K
11 Blair William & Co/Il 0.00% 912,513 $1.2M
12 Tamar Securities, LLC 0.00% 23,795 $31K
13 Baker Ellis Asset Management LLC 0.00% 20,000 $26K
14 AlphaCore Capital LLC 0.00% 108,493 $141K
15 Capital Advisors Wealth Management, LLC 0.00% 15,525 $20K
16 Scarborough Advisors, LLC 0.00% 10,502 $16K
17 Axq Capital, LP 0.00% 13,110 $17K
18 XTX Topco Ltd 0.00% 97,400 $127K
19 Security National Bank 0.00% 9,767 $13K
20 Essential Partners LLC 0.00% 2,085 $3K
21 Glenview Trust Co 0.00% 43,128 $70K
22 PFG Investments, LLC 0.00% 20,501 $27K
23 Trust Co of Toledo NA /Oh/ 0.00% 9,000 $12K
24 Golden State Wealth Management, LLC 0.00% 7,050 $9K
25 Hrt Financial LP 0.00% 272,786 $354K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Cardiff Oncology Inc (CRDF)

What does the Smart Money Trend signal show for CRDF?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their CRDF positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for CRDF?

Slight buying edge — 50% buying: Last quarter: 59 funds bought or added vs 60 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for CRDF holders?

Strong quality — 31% AUM from major funds: 28 of 105 holders rank in the top 100 by AUM, accounting for 31% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CRDF?

47% of holders stayed for 2+ years: 50 out of 106 hedge funds have held CRDF for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Cardiff Oncology Inc (CRDF) following the 2026 Q2 hedge fund 13F filings?

As of today, CRDF has moved +29.2% since the 2026 Q2 13F filing date (August 14, 2026), compared to +2.4% for the XLV sector ETF — an outperformance of +26.8%. Since the quarter end (June 30, 2026), CRDF has gained -4.6% vs +8.0% for XLV. The stock has significantly outperformed its sector benchmark — the original entry opportunity has largely been captured by earlier investors.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →